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Posterior microphthalmos (MCOP) is a rare isolated developmental anomaly of the eye characterized by extreme hyperopia due to short
axial length. The population of the Faroe Islands shows a high prevalence of an autosomal-recessive form (arMCOP) of the disease. Based
on published linkage data, we reﬁned the position of the disease locus (MCOP6) in an interval of 250 kb in chromosome 2q37.1 in two
large Faroese families. We detected three different mutations in PRSS56. Patients of the Faroese families were either homozygous for
c.926G>C (p.Trp309Ser) or compound heterozygous for c.926G>C and c.526C>G (p.Arg176Gly), whereas a homozygous 1 bp duplica-
tion (c.1066dupC) was identiﬁed in ﬁve patients with arMCOP from a consanguineous Tunisian family. In one patient withMCOP from
the Faroe Islands and in another one from Turkey, no PRSS56 mutation was detected, suggesting nonallelic heterogeneity of the trait.
Using RT-PCR, PRSS56 transcripts were detected in samples derived from the human adult retina, cornea, sclera, and optic nerve. The
expression of the mouse ortholog could be ﬁrst detected in the eye at E17 and was maintained into adulthood. The predicted PRSS56
protein is a 603 amino acid long secreted trypsin-like serine peptidase. The c.1066dupC is likely to result in a functional null allele,
whereas the two point mutations predict the replacement of evolutionary conserved and functionally important residues. Molecular
modeling of the p.Trp309Ser mutant suggests that both the afﬁnity and reactivity of the enzyme toward in vivo protein substrates
are likely to be substantially reduced.Microphthalmos (MCO) is a developmental anomaly
resulting from diverse pathomechanisms and character-
ized by small malformed eyes(s). When the condition
occurs in the absence of other ocular defects, it is called
isolated or pure microphthalmos. Autosomal-recessive
isolated posterior microphthalmos (arMCOP) deﬁnes a
rare distinct phenotype restricted to the posterior segment
of the eye (MIM 613517). In adults, isolated arMCOP is
clinically characterized by extreme hyperopia (from þ7.5
to þ21 diopters) due to short axial length (14–20 mm
compared to normal >21 mm), with essentially normal
anterior segment, steep corneal curvatures, shallow ante-
rior chamber, thick lenses, and thickened scleral wall.1–3
Palpebral ﬁssures appear narrow because of relatively
deep-set eyes, visual acuity is mildly to moderately
reduced, and anisometropic or strabismic amblyopia is
common. The fundus of the eye shows crowded optical
discs, tortuous vessels, and an abnormal foveal avascular
zone.1,4,5 In addition, papillomacular folds are often re-
ported.6–10 Morphometric features of the small eyes predis-
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neity is seen to affect, at a minimum, corneal curvature
and papillomacular folds.2,15
The gene mutated in isolated arMCOP has not yet been
identiﬁed. By a genome-wide linkage analysis (homozy-
gosity mapping) in ﬁve consanguineous Tunisian families
with isolated arMCOP, the disease locus (MCOP6) was
mapped between D2S2340 and D2S331, corresponding
to a genomic interval of about 2.65 Mb in chromosome
2q37.1.2 In two-point analysis, locus D2S2344 showed
close linkage and no recombination with MCOP6 with
a maximum LOD score of z ¼ 8.85 at Q ¼ 0.00. Four of
the ﬁve families were shown to share the same haplotype
in the critical interval, suggesting the presence of a founder
mutation in the families studied. The analysis of ﬁve posi-
tional candidate genes (SAG [MIM 181031], PDE6D [MIM
602676], CHRND [MIM 100720], CHRNG [MIM 100730],
and KCNJ13 [MIM 603208]) did not reveal any disease-
causing mutations in the Tunisian families.2
An unusually high prevalence of arMCOP has been re-
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Figure 1. Mapping the MCOP6 Locus in a Branch of Family
HOP000201 by the Analysis of Multiple Informative Meioses
Alleles of a total of ten DNA polymorphisms in the region between
D2S427 and D2S206 on chromosome 2q37.1 are arranged as prob-
able haplotypes. Individuals V.2 and VI.2 carry recombinant chro-
mosomes, suggesting that the MCOP6 locus maps between ALPP
and EFHD1. Generation and individual numbers shown in the
ﬁgure are the same as in Figure S1.The approximately 48,000 inhabitants represent a geneti-
cally isolated population, and in such cases rare genetic
diseases are often due to founder mutations (identity by
descent). We performed clinical studies and ascertained
several Faroese families with arMCOP.1,3,15 In addition, we
examined the medical records of approximately 30,000
outpatients visiting the Ophthalmology Department of the
National Hospital in To´rshavn, Faroe Islands, between 1967
and 2006, as well as an earlier archive dating back to 1947–
1966. The selection criterion of patients from the ophthal-
mological ﬁles was hypermetropia R þ10 diopters.1,3,15 In
this way, we identiﬁed 23 additional patients with MCOP.
Based on the mapping information obtained in the
Tunisian families,2 we genotyped all available members
of two large Faroese families with arMCOP (HOP00201
and HOP00202; see Figure S1 available online) in an initial
two-point linkage analysis for a total of nine microsatellite
markers on 2q37.1 between D2S427 and D2S395 covering
a region of about 25 cM. We assumed autosomal-recessive
inheritance with complete penetrance, but, in order to
avoid biasing the outcome, homozygosity due to identity
by descent was not required at this stage. Close linkage
without recombination was observed between MCOP6
and D2S2344 with maximum LOD scores of 4.79 at Q ¼
0.00 (data not shown). Positive LOD scores with zmax of
1.74–2.76 at Q ¼ 0.05 were also obtained in two-point
linkage analyses between MCOP6 and D2S427, between
MCOP6 and D2S206, and between MCOP6 and
D2S2348, loci known to map close to D2S2344. Analysis
of multiple informativemeioses in the two Faroese families
assigned MCOP6 between D2S2193 and D2S206, a region
spanning about 1.5 Mb (Figure S2).
Twoattractive candidategenes are assigned to the interval
between D2S2193 and D2S206: B3GNT7, encoding UDP-
GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase
7, an enzyme involved in the synthesis of corneal keratan
sulfate glycosaminoglycans, and KCNJ13, a member of the
subfamily J of inwardly rectifying potassiumchannel genes.
Mutations in the latter gene are associated with autosomal-
dominant snowﬂake vitreoretinal degeneration (MIM
193230). No pathogenic KCNJ13 mutation was found in
the patients with arMCOP from the Tunisian cohort.2 No
likely disease-causing variant was detected in the genes
SNORA75 (small nucleolar RNA, H/ACA box 75), SNORD20
(small nucleolar RNA, C/D box 20),NMUR1 (neuromedinU
receptor 1; MIM 604153), or PTMA (prothymosin, alpha;
MIM 188390) in the DNA samples of the two patients
fromeachof theFaroese families analyzed (datanot shown).
Comparison of individual genotypes of patients for intra-
genic polymorphisms detected in B3GNT7, NCL (MIM
164035), NMUR1, ALPP (MIM 171800), ECEL1 (MIM
605896), EFHD1 (MIM 611617), and KCNJ13 mapping
within the1.5Mbregionexcluded thepossibility thatmuta-
tions of any of these genes are causative for the arMCOP in
the Faroese families (data not shown and Figure S2).
In order to reduce the critical interval beyond that
deﬁned with the microsatellite markers used so far, weThe Amerianalyzed the segregation of six SNP alleles identiﬁed in
genes mapped in the critical region (Table S1) in all
members of the two families. The data obtained in a small
nuclear family within pedigree HOP00201 are shown in
Figure 1. The maternal haplotype of patient V.2 is a re-
combinant one that differs from that of his two affected
sisters (V.5 and V.6) at the loci EFHD1, KCNJ13, and
D2S206, suggesting that MCOP6 maps proximal to
EFHD1. Individual VI.2, the unaffected daughter of V.2,
carries the recombinant haplotype of her affected father,
i.e., the one segregating with the MCOP phenotype in
this family, as does the affected daughter (VI.1) of indi-
vidual V.2. Individual VI.2 also carries a recombinant
maternal chromosome with the same haplotype for the
interval D2S427–ALPP as her affected sister VI.1, but
different alleles for the genomic region D2S2344–
D2S206. Because individual VI.2 is unaffected, these data
suggest that MCOP6 maps distal to ALPP. Together, the
data map MCOP6 in a genomic interval of about 250 kb
between ALPP and EFHD1 (Figure S2). However, it is
remarkable that both patients V.2 and VI.1 are heterozy-
gous for the polymorphism at D2S2344, a locus mapped
in the critical interval. This observation contradicts our
initial hypothesis of an autosomal-recessive trait with
a single founder mutation and instead suggests that—at
least in some patients—two different mutations of the
same gene may be responsible for the phenotype.can Journal of Human Genetics 88, 382–390, March 11, 2011 383
Figure 2. Electropherograms of DNA
Sequences of PCR Amplicons
(A–F) The panels show the homozygous
c.1066dupC and c.926G>C mutations of
PRSS56 in patients NB8 (B) and III.5/
HOP000202 (D) and the heterozygous
c.526C>G mutation in V.2/HOP000201
(F), as well as the corresponding regions
in controls (wild-type, WT; A, C, and E,
respectively). DNA and predicted amino
acid (one letter code) sequences are shown
on the top of the ﬁgure.Therefore, we selected a pool of 29 patients with arMCOP,
two from each of the large families, 23 from small nuclear
families from the Faroe Islands, one (SE) from a small
consanguineous family from Turkey, and one (NB8) from
a large consanguineous family from Tunisia, to screen for
mutations in candidate genes in our subsequent studies.
PRSS56 (protease serine 56; also known as LOC646960)
encodes a protein of 603 amino acids (GenBank RefSeq:
NM_001195129 and NP_001182058) showing similarity
to trypsin-like serine proteases. Expressed sequence tag
data suggest that PRSS56 is expressed in embryonic tissue,
testis, brain, and eye. We PCR ampliﬁed the 13 coding
exons with short adjacent intronic sequences of PRSS56
(see Table S2) and found, in addition to known SNPs, three
very likely disease-causing mutations. In patient NB8 from384 The American Journal of Human Genetics 88, 382–390, March 11, 2011Tunisia, a homozygous 1 bp duplica-
tion (c.1066dupC) was identiﬁed
that results in a shift in the reading
frame, inclusion of PRSS56-unrelated
residues, a premature stop codon
(p.Gln356ProfsX152), and, most
likely, a functional null allele (Fig-
ure 2B). The mutation was shown to
cosegregate with the disease pheno-
type in the family consisting of
healthy consanguineous parents and
a total of 11 children, ﬁve of them
affected. The ophthalmological
picture in the family consists of nano-
phthalmos with microcornea (9–
10 mm, mean of 9.75 mm), shallow
anterior chamber and angle, extreme
hyperopia (þ10 to þ18 diopters;
mean of 14 diopters), short axial
length (15.4–17.6 mm; mean of
16.15 mm), high lens/eye volume
ratio (mean of 29%), thick sclera and
choroid, and absence of overt struc-
tural defects (unlike microphthalmia).
Best corrected vision ranged between
0.05 and 0.5 (mean of 0.27). Fundus
abnormality was seen in ﬁve eyes
(papillomacular fold [n ¼ 3],
a choroidal neovascular membrane[n ¼ 1], and a central venous occlusion secondary to
angle-closure glaucoma [n ¼ 1]). Phenotypes in the Tuni-
sian families reported by Hmani-Aifa et al.2 differ from
the phenotype in this family with respect to normal
corneal diameter and steepness.
All but one of the patients of the Faroese cohort (n ¼ 27;
two from each of the large families and 23 ‘‘sporadic’’ cases)
carried a PRSS56 mutation: a c.926G>C change in exon 8
(p.Trp309Ser; Figure 2D) in homozygous form (n ¼ 20) or
compound heterozygous form (n ¼ 6) with c.526C>G
(p.Arg176Gly) in exon 5 (Figure 2F). We also genotyped
all members of the two families for the c.526C>G and
c.926G>C mutations (Figure S1) and showed cosegrega-
tion of the variants with the disease phenotype. Consistent
with the 1 bp duplication in the Tunisian family that
should result in a loss-of-function allele, the two Faroese
point mutations result in the replacement of evolution-
arily conserved and functionally important residues and
are likely to lead to reduced catalytic activity of the protein.
The phenotype of the Faroese patients is very similar to
that seen in the Tunisian family of NB8, except for the
corneal diameter, which is described as microcornea in
the Tunisian family, whereas corneal diameters in the
Faroese subjects are normal, albeit in the lower range.
The modest differences among, and the partial overlap
of, the phenotypes of the patients in the Faroese families
and the NB8 Tunisian family suggest that a distinction
between posterior microphthalmos and nanophthalmos
might be artiﬁcial, thus leading to the view that these
two conditions represent a continuum of phenotypes.
We genotyped selected patients for polymorphisms of
the genes mapped within the 250 kb interval. Of the 20
patients carrying a homozygous c.926G>C PRSS56 muta-
tion, one was heterozygous for the G-to-C change of the
rs6750085 SNP of ECEL1. This observation can be ex-
plained by a putative recombination between ECEL1 and
PRSS56, conﬁrms that MCOP6 maps between ECEL1 and
EFHD1, and thus reduces the critical interval to about
150 kb (Figure S2). In addition to PRSS56, this interval
contains four other positional candidate genes: CHRND,
CHRNG, TIGD1 (tigger transposable element derived 1;
MIM 612972), and EIF4E2 (eukaryotic translation initia-
tion factor 4E, family member 2; MIM 605895;
Figure S2). In the DNA sample of a Faroese patient homo-
zygous for the PRSS56 c.926G>C mutation, only very
likely nonpathogenic variants were found by sequencing
all coding exons of TIGD1 (c.252G>A [rs4973540] and
c.822G>A [rs6752614]) and EIF4E2 (c.213þ48delT). Muta-
tion analysis of CHRND and CHRNG was performed by
Hmani-Aifa et al. in patients from the Tunisian families
with arMCOP and did not reveal any disease-causing
changes.2
Genealogical studies identiﬁed a married couple (born in
1598 and 1631) as ancestors of the parents of all arMCOP
patients from the Faroe Islands carrying the c.926G>C
mutation in homozygous or heterozygous state genotyped
in this study. None of the three PRSS56 sequence variants
found were detected on 100 chromosomes of unaffected
German controls. However, three out of 94 anonymous
unaffected Faroese controls genotyped in this study were
heterozygous for the c.926G>C mutation, corresponding
to a heterozygote frequency of 3.2%. This ﬁnding is in
line with the incidence of heterozygotes for other disorders
in the Faroe Islands caused by founder mutations, e.g.,
mitochondrial encephalomyopathy caused by SUCLA2
(MIM 603921) mutations16 and retinitis pigmentosa due
to MERTK (MIM 604705) mutations.17 The c.526C>G
mutation was not found in the 94 controls. Genealogical
studies identiﬁed a male born in 1827 as the ancestor of
all Faroese arMCOP patients carrying the c.526C>Gmuta-
tion in compound heterozygous state. On the one hand,
the likely younger age of the c.526C>G change explainsThe Amerithe predominance of the c.926G>C variant in both
patients and controls. On the other hand, the high
number of patients carrying the c.526C>G mutation in
heterozygous state in family HOP00201 is unexpected.
However, this observation can easily be explained by
assuming that one of the parents (1 or 1a) in generation I
carried the c.526C>G variant and transmitted it to both
his/her children, whereas the c.926G>C change was
contributed by one of the other parents (2 or 2a) in gener-
ation I (Figure S1).
In two patients, one from the Faroe Islands and the
other, patient SE, from Turkey, we sequenced all exons of
PRSS56 and found that they did not carry any of the muta-
tions identiﬁed in other patients of this study or any other
disease-related changes. Similarly, exon-spanning PCR am-
plicons did not reveal any size difference following nonde-
naturing electrophoretic separation compared to control
amplicons, making the presence of a larger, exon-spanning
deletion or insertion unlikely and suggesting nonallelic
heterogeneity of MCOP. This assumption is further
substantiated by the fact that patient SE from a consan-
guineous family was heterozygous for two different SNPs
in PRSS56 (data not shown).
We evaluated the expression of PRSS56 via RT-PCR with
gene-speciﬁc primers (Table S3) to amplify cDNAs gener-
ated from equal amounts of total RNAs isolated from
human donor eye tissues. PRSS56 transcripts were abun-
dant in the samples derived from the neural retina, cornea,
sclera, and optic nerve (Figure 3A). To evaluate expression
during development, we PCR ampliﬁed Prss56 (also called
1700027L20Rik, the mouse ortholog of the human
PRSS56) from cDNAs generated from total RNAs isolated
from mouse eyes (embryonic day 12 through postnatal
day 1) and mouse retinas (postnatal day 5 through adult).
Prss56 transcripts were ﬁrst detected at embryonic day 17,
with expression maintained into adulthood (Figure 3B).
The expression of Prss56 was also evaluated by in situ
hybridization (Figure 4). Images of nonpigmented mouse
eyes in cross-section (top panels) show that speciﬁc (anti-
sense) signals were obtained in the retina and in the optic
nerve (seen as punctate staining), whereas nonspeciﬁc
staining artifacts were observed in lens fragments. At
higher magniﬁcation (bottom panels), strong reactivity
was seen in the retinal ganglion cells, moderate reactivity
in the inner nuclear layer, and low-level reactivity in the
outer nuclear layer and other eye tissues (Figure 4). No reac-
tivity was detected in E16 mouse eye tissue (data not
shown). Taken together, these data suggest a unique
requirement for PRSS56 in the physiology of the neural
retina.
Based on the little data available to date, Prss56 shows
a limited expression in the mouse nervous system. Coulp-
ier et al.18 reported that 1700027L20Rik (Prss56) is amarker
for embryonic boundary cap (BC) cells, a transient popula-
tion of cells of neural crest origin. BC cells form clusters at
the surface of the neural tube, at entry and exit points of
peripheral nerve roots (i.e., at the boundary betweencan Journal of Human Genetics 88, 382–390, March 11, 2011 385
Figure 4. In Situ Hybridization of Sections of a 3-Month-Old
Balb/c Mouse Eye with Prss56 RNA Probes
Sagittal sections were hybridized with digoxygenin-labeled anti-
sense and sense RNA probes transcribed from a 411 bp fragment
of the Prss56 cDNA (accession number JF323950; ampliﬁed with
primer pair 2 from P12 mouse retina RNA; see Table S3 for
primers). Probes were detected with alkaline phosphatase-coupled
anti-DIG antibodies, followed by staining in Nitro-Blue Tetrazo-
lium/5-Bromo-4-Chloro-30-Indolyphosphate (NBT/BCIP; Roche)
for 4 hr at 37C. Sectionswere viewedwith a Zeiss Axiophotmicro-
scope equipped with differential interference contrast optics and
a Kappa camera. Scale bars represent 0.5 mm (top panels) and
20 mm (bottom panels).
Figure 3. Expression Analysis
(A) RT-PCR products fromhuman eye tissues. The following abbre-
viations are used: Ret, retina; RPE, retinal pigment epithelium/
choroid; CB, ciliary body; Irs, iris; Crn, cornea; Scl, sclera; ON,
optic nerve.
(B) RT-PCR products from mouse eye and retinas at the ages
shown.
Total RNAwas isolated fromhuman donor (male, 60 yr) eye tissues
obtained within 20 hr postmortem. Mouse total RNA was isolated
from whole eyes of C57Bl/6 at embryonic day ages E12, E14, and
E17 and postnatal day ages P0 and P1, as well as from dissected
retinas at ages P5, P12, and adult (Ad). RNA concentrations and
integrity were evaluated with Agilent Bioanalysis. First-strand
cDNAs were prepared from 1 mg RNA with Superscript II, followed
by treatment with RNase H. DNA sequences were PCR ampliﬁed
with primers for PRSS56, Prss56, and the hypoxanthine phosphor-
ibosyltransferase gene (HPRT; Table S3) by using 35 cycles of 94C
for 1 min, 55C for 1 min, and 68C for 2 min. The products were
visualized on agarose gels stained with SyberGreen.central and peripheral nervous system), and give rise to
neuron and glia cells. We found that Prss56 is highly ex-
pressed in retinal ganglion cells of adult animals. Although
the functional relation between retinal ganglion cells and
BC cells is unknown, we conclude that this putative
protease is expressed in different populations of highly
specialized neural cells.
Analysis of the predicted PRSS56 protein sequence
showed that it may be classiﬁed as a serine peptidase of
the chymotrypsin family (clan PA, family S1 according to
Merops Peptidase Database).19 We performed molecular
modeling with the SWISS-MODEL server in automated
mode and based on the best possible alignment toward
proteinspresent in theResearchCollaboratory for Structural
Bioinformatics protein database (pdb). The PRSS56 protein
sequence (both wild-type and the p.Trp309Ser mutant) ex-
hibited the highest similarity to the catalytic domain of en-
teropeptidase (pdb entry 1ekbB). However, enteropeptidase
does not carry tryptophan, but instead carries phenylala-
nine in position 263 (corresponding to position 309 in
PRSS56), and thus it may not be the best model to analyze
the effect of thep.Trp309Sermutation. Therefore,modeling
was based on trypsin (2agg) that carries tryptophan at this
position (Trp215 in trypsin). The enteropeptidase- and
trypsin-based models were largely comparable, because in
both cases Trp309 adopted a similar position lining part of386 The American Journal of Human Genetics 88, 382–390, March 1the substrate-binding pocket. As shown in Figure 5, several
features of the PRSS56 sequence clearly support its assign-
ment to the chymotrypsin family. (1) Like other members
of this family, PRSS56 is predicted to be a secreted protein
with an N-terminal signal peptide that directs the protein
into the secretory pathway (Figure 5A). (2) Members of
this family are secreted as catalytically inactive proenzymes
that require proteolytic cleavage at a highly conserved posi-
tion to convert the enzyme to the active form. The sequence
around the cleavage site (residues 104–105) is conserved in1, 2011
Figure 5. Trypsin-Like Serine Protease PRSS56
(A) Schematic structure of PRSS56. Positions of the signal peptide (SP, cleaved between residues 19 and 20), the cleavage site of the pro-
protein (residues104–105), and the protease domain are indicated. The C-terminal domain of the protein does not exhibit similarity to
any known protein.
(B) Alignment of functionally relevant sequence elements of members of the serine-protease family. The position of the cleavage site for
conversion of the proenzymes into the active enzymes is indicated (trypsinogen to trypsin, prothrombin to thrombin, etc.); the
sequence N-terminal to the cleavage site is underlined. Elements of the charge relay system or catalytic triad (Asp191/His145/Ser286
in PRSS56), as well as an aspartate residue localized in the P1 speciﬁcity pocket (Asp280 in PRSS56), and the sequence surrounding
Trp309 are indicated by bold print.
(C) 3Dmodel of wild-type (left) andp.Trp309Sermutant (right) PRSS56 based on the atomic structure of trypsin.Molecularmodelingwas per-
formedwith the SWISS-MODEL server in automatedmode. PDBdata sets obtainedby themodelingprocedurewere visualizedwith thehelpof
the polyview 3D visualization server. Residues Trp309-Gly310 and the catalytic Ser286 (red) are indicated by stickmodels, and the negatively
chargedAsp280 at the bottomof the P1 active-site pocket is shown inblue. In thewild-type, Trp309 togetherwith residues Phe188 (F), Leu260
(L), andPro262(P)contributes tothe formationofashallowhydrophobiccavity (yellowsurface),which isdisrupted inthep.Trp309Sermutant.
(D) Sequence alignment of vertebrate homologs of PRSS56. Sequences ﬂanking Arg176 and Trp309 are shown. Identical amino acids are
indicated by dots.
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PRSS56. (3)PRSS56carries a charge relay system(also termed
catalytic triad) consisting of Asp191-His145-Ser286 (similar
to Asp102-His57-Ser195 in trypsin), which is required for
thenucleophilic activityof thecatalytic Ser286.19 (4)Amino
acids involved in substrate binding are conserved in PRSS56
(Figure 5B). Asp280 (corresponding to Asp189 in trypsin) is
located at the bottom of the rather deep pocket of the pre-
dicted active site (blue in Figure 5C) in a position to stabilize
positively charged Arg/Lys side chains of the substrate
through its negative charge.20,21 In addition, residues
Ser308-Trp309-Gly310 are in a position to forma secondary
binding pocket that can contribute to speciﬁcity by accom-
modating the side chains of residues N terminal to this Arg/
Lys residue.
Proteases of the chymotrypsin family exhibit variable
degrees of substrate speciﬁcity. On the one hand, trypsin
shows little speciﬁcity, because the presence of a positively
charged Arg or Lys immediately C-terminal to the cleavage
site is sufﬁcient for substrate recognition. On the other
hand, catalytic activity of other members of this protein
family, such as enteropeptidase or thrombin, is highly
sequence speciﬁc. In most cases, residues N-terminal to
the Arg/Lys residue contribute to speciﬁcity as their side
chains are accommodated by a shallow pocket adjacent
to the active site. The sequence around Trp215 (Trp309
in PRSS56) is highly conserved among trypsin-like
enzymes and is also predicted to contribute to formation
of this pocket in PRSS56. In the case of thrombin, the cor-
responding Trp215 residue has been shown to be essential
for efﬁcient binding of hydrophobic residues of the
substrate, and analysis of mutant proteins generated by
in vitro mutagenesis indicated that this residue is the
primary determinant of substrate selectivity.22,23
Molecular modeling of the wild-type and p.Trp309Ser
mutant forms of PRSS56 suggests that p.Trp309, together
with Phe188, Leu260, and Pro262, forms a hydrophobic
cavity that may be required to accommodate hydrophobic
residues of the substrate. Modeling of the mutant form
suggests that a serine at position 309 leads to a much wider
pocket and a disruption of the hydrophobic surface as
a result of insertion of the small and hydrophilic serine
side chain (Figure 5C). These changes are likely to disrupt
binding of one or more in vivo substrates of PRSS56, sug-
gesting that afﬁnity and reactivity toward the (so far
unknown) natural substrates of PRSS56 are likely to be
reduced substantially. The second missense mutation,
p.Arg176Gly, affects a residue that is evolutionarily highly
conserved in all vertebrate orthologs of PRSS56
(Figure 5D). In 3D models, it is distant from the active
site and thus is not likely to directly participate in substrate
binding. Arg176 may interact with a helical segment at the
C-terminal end of the protease domain. Loss of this inter-
action in the mutant leads to very subtle conformational
changes in a number of amino acids in the vicinity of
the catalytic Ser286 (data not shown). This suggests
a possible effect of the p.Arg176Gly mutation on catalytic
efﬁciency, which can only be experimentally ascertained388 The American Journal of Human Genetics 88, 382–390, March 1once the in vivo substrate or substrates of the PRSS56
protease are identiﬁed. Alternatively, loss of Arg176 might
affect the solubility of the protein, leading to aggregation.
Sequence comparisons show that orthologs of PRSS56
exist in all vertebrate species analyzed (Figure 5 and data
not shown). Similarity is high between the human protein
and its mammalian counterparts. In particular, all
sequence elements required for processing of the protein
and all residues likely to be involved in catalysis are highly
conserved (see Figure 5). In addition, the C-terminal
region, which does not contain any obvious functional
motifs, is very similar in different mammalian species, sug-
gesting that it is also relevant for the function of the
PRSS56 protein. In other vertebrates such as zebraﬁsh,
the catalytic domain is more highly conserved than the
C-terminal domain. No PRSS56 orthologs in nonvertebrate
species could be detected, suggesting a function unique to
the development of the vertebrate visual system.
The mouse homolog of PRSS56 has been described as
a protein of unknown function with high similarity to
the transmembrane serine protease 9.18,24 This protein,
also known as polyserase-I, consists of an N-terminal cyto-
plasmic segment followed by a type II transmembrane
domain and three independent trypsin-like serine protease
domains. However, the similarity between PRSS56 and
poyserase-I is limited to the protease domains, whereas
the overall domain structure is different. As mentioned
above, the PRSS56 protein is predicted to be processed in
the secretory pathway because of a cleavable N-terminal
signal peptide, whereas the transmembrane serine protease
was shown to be an integral membrane protein localized
on the cell surface.25
Postnatal development of the ocular refractive compo-
nents is a tightly regulated adaptiveprocess bywhichoptical
defocus leads to changes in axial length moving the retina
toward the image plane. This emmetropization process
involves a retinal feedback mechanism. The concept of
such mechanism is underscored by evidence from experi-
mental myopia. The postnatal increase in axial length of
the eye is mainly due to an elongation of the posterior
segment from 10–11 mm at birth to 15–16 mm at the age
of 13.26 The pathophysiology involved inMCOPmay theo-
retically be explained by a postnatal growth retardation of
the posterior segment (axial length of the vitreous), in accor-
dance with the expression pattern of PRSS56. The corneal
changes, however, may indicate the presence of a prenatal
action. Very little is known about the molecular pathways
involved in this remodeling. It is, however, tempting to
anticipate the involvement of secreted peptidases in cata-
lytic processes in the vitreous and/or the sclera. We propose
that theproteolytic activityprovidedbytheproteinencoded
by PRSS56 is essential for this process during development.Supplemental Data
Supplemental Data include three tables and two ﬁgures and can be
found with this article online at http://www.cell.com/AJHG/.1, 2011
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